CN114980915A - 轻度创伤性脑损伤的治疗 - Google Patents

轻度创伤性脑损伤的治疗 Download PDF

Info

Publication number
CN114980915A
CN114980915A CN202080092650.7A CN202080092650A CN114980915A CN 114980915 A CN114980915 A CN 114980915A CN 202080092650 A CN202080092650 A CN 202080092650A CN 114980915 A CN114980915 A CN 114980915A
Authority
CN
China
Prior art keywords
ghrelin
variant
mtbi
days
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092650.7A
Other languages
English (en)
Chinese (zh)
Inventor
V·班萨尔
K·莎阿
M·威安德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxia Biopharmaceuticals
Original Assignee
Oxia Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxia Biopharmaceuticals filed Critical Oxia Biopharmaceuticals
Publication of CN114980915A publication Critical patent/CN114980915A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080092650.7A 2019-12-23 2020-12-22 轻度创伤性脑损伤的治疗 Pending CN114980915A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953130P 2019-12-23 2019-12-23
US62/953,130 2019-12-23
PCT/US2020/066703 WO2021133844A1 (en) 2019-12-23 2020-12-22 Treatment of mild traumatic brain injury

Publications (1)

Publication Number Publication Date
CN114980915A true CN114980915A (zh) 2022-08-30

Family

ID=76575665

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092650.7A Pending CN114980915A (zh) 2019-12-23 2020-12-22 轻度创伤性脑损伤的治疗

Country Status (11)

Country Link
US (1) US20230031262A1 (https=)
EP (1) EP4081238A4 (https=)
JP (1) JP2023508250A (https=)
KR (1) KR20220122691A (https=)
CN (1) CN114980915A (https=)
AU (1) AU2020412765A1 (https=)
BR (1) BR112022012365A2 (https=)
CA (1) CA3165738A1 (https=)
IL (1) IL294156A (https=)
MX (1) MX2022007844A (https=)
WO (1) WO2021133844A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370804A1 (en) * 2021-01-22 2022-11-24 The Regents Of The University Of Colorado, A Body Corporate Motor learning and vagus nerve stimulation (vns) paired with motor learning to treat demyelinating diseases, conditions and disorders
CN113723530B (zh) * 2021-09-02 2022-03-25 中国科学院自动化研究所 基于视频分析和电子心理沙盘的智能心理评估系统
AU2023338304A1 (en) * 2022-09-07 2025-04-10 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150216939A1 (en) * 2014-02-05 2015-08-06 Vishal Bansal Methods of treating mild brain injury
CN106573014A (zh) * 2014-04-29 2017-04-19 梯瓦制药工业有限公司 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德
US20170121385A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US20170281732A1 (en) * 2014-08-19 2017-10-05 Oxeia Biopharmaceuticals, Inc. Methods of treating mild brain injury

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6545697B2 (ja) * 2013-11-15 2019-07-17 ニューラル・アナリティクス・インコーポレーテッド 神経学的状態の診断のための脳の血流速度の構造的特徴をモニタリングすること
WO2016134215A1 (en) * 2015-02-19 2016-08-25 The Regents Of The University Of California Methods of treating mild brain injury and post-traumatic stress disorder
US20180071367A1 (en) * 2015-03-09 2018-03-15 Oxeia Biopharmaceuticals, Inc. Methods of treating cognitive impairments or dysfunction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150216939A1 (en) * 2014-02-05 2015-08-06 Vishal Bansal Methods of treating mild brain injury
CN106573014A (zh) * 2014-04-29 2017-04-19 梯瓦制药工业有限公司 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德
US20170281732A1 (en) * 2014-08-19 2017-10-05 Oxeia Biopharmaceuticals, Inc. Methods of treating mild brain injury
US20170121385A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEZZEH HOSSIENZADEH等: "Effect of ghrelin on brain edema induced by acute and chronic systemic hypoxia", 《NEUROSCIENCE LETTERS》, vol. 534, no. 8, 4 January 2013 (2013-01-04), pages 47 - 51, XP028964264, DOI: 10.1016/j.neulet.2012.11.062 *

Also Published As

Publication number Publication date
BR112022012365A2 (pt) 2022-08-30
CA3165738A1 (en) 2021-07-01
JP2023508250A (ja) 2023-03-01
US20230031262A1 (en) 2023-02-02
AU2020412765A1 (en) 2022-07-14
WO2021133844A1 (en) 2021-07-01
EP4081238A4 (en) 2023-08-30
EP4081238A1 (en) 2022-11-02
MX2022007844A (es) 2022-09-07
IL294156A (en) 2022-08-01
KR20220122691A (ko) 2022-09-02

Similar Documents

Publication Publication Date Title
Friedman et al. Diazepam is no better than placebo when added to naproxen for acute low back pain
Calderón et al. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real‐life clinical assessment
Warden et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury
Brown et al. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial
Cameron et al. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache
CN114980915A (zh) 轻度创伤性脑损伤的治疗
Proctor et al. A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: findings from a retrospective multisite study.
Gelkopf et al. Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic
Hallas et al. Methodological analysis: randomized controlled trials for pfizer and moderna COVID-19 vaccines
Singappuli et al. Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions
Buta et al. Real-world evidence of allergen immunotherapy
Peng et al. Polypharmacy and potential drug–drug interactions among people living with HIV in the era of integrase strand transfer inhibitor-based antiretroviral therapy
Mösges et al. Dose-finding study of carbamylated monomeric allergoid tablets in grass-allergic rhinoconjunctivitis patients
Vial et al. Smoking cessation program using nicotine patches linking hospital to the community
Fugate et al. Prospective study of medication adherence pattern in chronic obstructive pulmonary disease and asthma patient’s in tertiary care teaching hospital
Attallah et al. Efficacy, safety and quality of life of oxybutynin versus aluminum chloride hexahydrate in treating primary palmar hyperhidrosis
七海陽子 et al. Effectiveness of pharmacists' comprehensive assessment of medication profiles in dementia patients
HK40080092A (en) Treatment of mild traumatic brain injury
US20260077018A1 (en) Treatment of mild traumatic brain injury
Subramanyan et al. Using automated pharmacy records to assess the management of tuberculosis
Manti et al. Efficacy and perceived satisfaction of 3-year SLIT in children with allergic rhinitis and asthma: A pilot study in real-life.
Nasser et al. Serotonin Syndrome Precipitated by Paxlovid Initiation
Khokhar et al. Vaccination counseling with and without excipient skin testing in patients with suspected allergic reactions to mRNA COVID-19 vaccines and patients with atopy
Yaeger et al. Ropivacaine intramuscular paracervical injections for pediatric headache: a randomized placebo-controlled trial
Melendez Evaluating impact of opioid detoxification lengths of stay on withdrawal symptoms upon discharge

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080092

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220830